Short Interest in Centogene (NASDAQ:CNTG) Drops By 20.1%
Short Interest in Centogene (NASDAQ:CNTG) Drops By 20.1%
Centogene (NASDAQ:CNTG – Get Rating) was the target of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 18,700 shares, a decrease of 20.1% from the June 30th total of 23,400 shares. Approximately 0.3% of the company's shares are sold short. Based on an average daily volume of 9,600 shares, the short-interest ratio is currently 1.9 days.
Centogene(納斯達克:CNTG-GET Rating)是空頭股數7月份大幅下降的目標。截至7月15日,空頭股數共有18,700股,較6月30日的23,400股減少20.1%。該公司約0.3%的股票被賣空。以日均成交量9,600股計算,短息比率目前為1.9天。
Centogene Stock Performance
世紀之交股票表現
NASDAQ CNTG opened at $1.55 on Thursday. The company has a market capitalization of $30.78 million, a price-to-earnings ratio of -0.64 and a beta of -1.18. Centogene has a twelve month low of $1.34 and a twelve month high of $11.61. The stock has a fifty day simple moving average of $2.24 and a 200 day simple moving average of $3.30. The company has a quick ratio of 2.41, a current ratio of 2.48 and a debt-to-equity ratio of 0.67.
新浪納斯達克週四開盤價為1.55美元。該公司市值為3,078萬美元,市盈率為-0.64倍,貝塔係數為-1.18。Centogene的12個月低點為1.34美元,12個月高位為11.61美元。該股的50日簡單移動均線為2.24美元,200日簡單移動均線為3.30美元。該公司的速動比率為2.41,流動比率為2.48,債務權益比率為0.67。
Centogene (NASDAQ:CNTG – Get Rating) last issued its quarterly earnings results on Friday, July 15th. The company reported ($0.54) earnings per share for the quarter. Centogene had a negative return on equity of 134.55% and a negative net margin of 35.35%. The business had revenue of $11.59 million for the quarter. Sell-side analysts expect that Centogene will post -1.72 EPS for the current year.
Centogene(納斯達克:CNTG-GET Rating)上一次發佈季度收益報告是在7月15日(星期五)。該公司公佈了本季度每股收益(0.54美元)。Centogene的淨資產回報率為負134.55%,淨利潤率為負35.35%。該業務本季度的收入為1159萬美元。賣方分析師預計,Centogene本年度每股收益將達到1.72歐元。
Institutional Trading of Centogene
世紀之交的機構交易
Analyst Ratings Changes
分析師評級發生變化
Separately, SVB Leerink decreased their price objective on Centogene from $10.00 to $6.00 and set an "outperform" rating for the company in a report on Monday, July 18th.
另外,SVB Leerink在7月18日週一的一份報告中將Centogene的目標價從10.00美元下調至6.00美元,併為該公司設定了“跑贏大盤”的評級。
Centogene Company Profile
Centogene公司簡介
(Get Rating)
(獲取評級)
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.
Centogene N.V.及其子公司專注於罕見疾病,將現實世界的臨牀和基因或其他數據轉換為可操作的信息,供世界各地的患者、醫生和製藥公司使用。它通過三個部門運作:製藥、診斷和新冠肺炎測試。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Centogene (CNTG)
- There Are Different Types of Stock To Invest In
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn't Ignore
- 免費獲取StockNews.com關於Centogene的研究報告(CNTG)
- 有不同類型的股票可供投資
- 是時候開發Molson Coors了,還是啤酒銷售會變得平淡?
- 星巴克是在向月球進軍嗎?
- PayPal繼續掙扎,競爭加劇
- 你不應該忽視的兩個高收益深度價值
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.
接受《世紀英文報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Centogene和相關公司的最新新聞和分析師評級的每日簡要摘要。